{"id":48291,"date":"2022-09-13T12:01:59","date_gmt":"2022-09-13T10:01:59","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/h-i-g-capital-completes-recapitalization-of-navitas-life-sciences\/"},"modified":"2022-09-13T12:01:59","modified_gmt":"2022-09-13T10:01:59","slug":"h-i-g-capital-completes-recapitalization-of-navitas-life-sciences","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/h-i-g-capital-completes-recapitalization-of-navitas-life-sciences\/","title":{"rendered":"H.I.G. Capital Completes Recapitalization of Navitas Life Sciences"},"content":{"rendered":"
\n

MIAMI–(BUSINESS WIRE)–#BlueChipClients<\/a>–H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with over $50 billion of equity capital under management, is pleased to announce that one of its affiliates has completed the recapitalization of Navitas Life Sciences (\u201cNavitas\u201d or the \u201cCompany\u201d).\n<\/p>\n

<\/a><\/p>\n

\nHeadquartered in Princeton, NJ, Navitas is a global technology-enabled clinical research organization (CRO) providing outsourced data science (including biostatistics, statistical programming, and data management), regulatory & safety services (including software and monitoring), and other full-service CRO capabilities to blue-chip large and mid-sized pharmaceutical and government clients. The Company\u2019s functional service expertise optimizes the clinical trial process, drives cost efficiencies for its clients, and ensures adherence to regulatory compliance requirements. The Company\u2019s global operations span the United States, India, Europe and South America.\n<\/p>\n

\n\u201cWe are delighted to partner with H.I.G. in our mission to accelerate global access to outstanding drug development outcomes by harnessing the power of technology and domain knowledge,\u201d said Srinivasan HR, Chief Executive Officer at Navitas. \u201cH.I.G., with its global network and diverse experience across healthcare and life sciences, is an ideal partner to support Navitas\u2019 continued growth as a Global Next Generation CRO. We are excited to leverage H.I.G.\u2019s capital and resources to accelerate our own growth initiatives while continuing to deliver outstanding service to our clients.\u201d\n<\/p>\n

\n\u201cNavitas\u2019 capabilities go well beyond a traditional CRO as the Company leverages its expertise and technology for innovation and growth,\u201d said Camilo E. Horvilleur, Managing Director at H.I.G. Capital. \u201cAs technology becomes an integral part of drug development value chain, we expect Navitas to become an increasingly important strategic partner to life sciences companies.\u201d\n<\/p>\n

\nAbout Navitas Life Sciences<\/strong>\n<\/p>\n

\nNavitas is a global technology-enabled clinical research organization (CRO) providing outsourced data science, regulatory & safety, and full-service CRO services to large and mid-sized pharmaceutical clients. The Company\u2019s functional service expertise optimizes the clinical trial process, drives cost efficiencies for its clients, and ensures adherence to regulatory compliance requirements.\n<\/p>\n

\nAbout H.I.G. Capital<\/b>\n<\/p>\n

\nH.I.G. is a leading global alternative assets investment firm with over $50 billion of equity capital under management.* Based in Miami, and with offices in New York, Boston, Chicago, Dallas, Los Angeles, San Francisco, and Atlanta in the U.S., as well as international affiliate offices in London, Hamburg, Madrid, Milan, Paris, Bogot\u00e1, Rio de Janeiro and S\u00e3o Paulo, H.I.G. specializes in providing both debt and equity capital to small and mid-sized companies, utilizing a flexible and operationally focused\/ value-added approach:\n<\/p>\n

    \n
  1. \nH.I.G.\u2019s equity funds invest in management buyouts, recapitalizations and corporate carve-outs of both profitable as well as underperforming manufacturing and service businesses.\n<\/li>\n
  2. \nH.I.G.\u2019s debt funds invest in senior, unitranche and junior debt financing to companies across the size spectrum, both on a primary (direct origination) basis, as well as in the secondary markets. H.I.G. is also a leading CLO manager, through its WhiteHorse family of vehicles, and manages a publicly traded BDC, WhiteHorse Finance.\n<\/li>\n
  3. \nH.I.G.\u2019s real estate funds invest in value-added properties, which can benefit from improved asset management practices.\n<\/li>\n
  4. \nH.I.G. Infrastructure focuses on making value-add and core plus investments in the infrastructure sector.\n<\/li>\n<\/ol>\n

    \nSince its founding in 1993, H.I.G. has invested in and managed more than 300 companies worldwide. The firm’s current portfolio includes more than 100 companies with combined sales in excess of $30 billion. For more information, please refer to the H.I.G. website at www.higcapital.com<\/a>.\n<\/p>\n

    \n* Based on total capital commitments managed by H.I.G. Capital and affiliates.\n<\/p>\n

    Contacts<\/b> <\/p>\n

    \nCamilo E. Horvilleur
    \n
    Managing Director
    \n
    chorvilleur@higcapital.com<\/a>\n<\/p>\n

    \nScott Zhu
    \n
    Principal
    \n
    szhu@higcapital.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

    MIAMI–(BUSINESS WIRE)–#BlueChipClients–H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with over $50 billion of equity capital under management, is pleased to announce that one of its affiliates has completed the recapitalization of Navitas Life Sciences (\u201cNavitas\u201d or the \u201cCompany\u201d). Headquartered in Princeton, NJ, Navitas is a global technology-enabled clinical research organization (CRO) providing outsourced … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48291","6":"format-standard","7":"category-industry"},"yoast_head":"\nH.I.G. Capital Completes Recapitalization of Navitas Life Sciences - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/h-i-g-capital-completes-recapitalization-of-navitas-life-sciences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"H.I.G. Capital Completes Recapitalization of Navitas Life Sciences - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"MIAMI–(BUSINESS WIRE)–#BlueChipClients–H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with over $50 billion of equity capital under management, is pleased to announce that one of its affiliates has completed the recapitalization of Navitas Life Sciences (\u201cNavitas\u201d or the \u201cCompany\u201d). Headquartered in Princeton, NJ, Navitas is a global technology-enabled clinical research organization (CRO) providing outsourced ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/h-i-g-capital-completes-recapitalization-of-navitas-life-sciences\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-13T10:01:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220913005455\/en\/1116880\/21\/New_HIGCapital.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/h-i-g-capital-completes-recapitalization-of-navitas-life-sciences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/h-i-g-capital-completes-recapitalization-of-navitas-life-sciences\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"H.I.G. Capital Completes Recapitalization of Navitas Life Sciences\",\"datePublished\":\"2022-09-13T10:01:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/h-i-g-capital-completes-recapitalization-of-navitas-life-sciences\\\/\"},\"wordCount\":627,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/h-i-g-capital-completes-recapitalization-of-navitas-life-sciences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220913005455\\\/en\\\/1116880\\\/21\\\/New_HIGCapital.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/h-i-g-capital-completes-recapitalization-of-navitas-life-sciences\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/h-i-g-capital-completes-recapitalization-of-navitas-life-sciences\\\/\",\"name\":\"H.I.G. Capital Completes Recapitalization of Navitas Life Sciences - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/h-i-g-capital-completes-recapitalization-of-navitas-life-sciences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/h-i-g-capital-completes-recapitalization-of-navitas-life-sciences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220913005455\\\/en\\\/1116880\\\/21\\\/New_HIGCapital.jpg\",\"datePublished\":\"2022-09-13T10:01:59+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/h-i-g-capital-completes-recapitalization-of-navitas-life-sciences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/h-i-g-capital-completes-recapitalization-of-navitas-life-sciences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/h-i-g-capital-completes-recapitalization-of-navitas-life-sciences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220913005455\\\/en\\\/1116880\\\/21\\\/New_HIGCapital.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220913005455\\\/en\\\/1116880\\\/21\\\/New_HIGCapital.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/h-i-g-capital-completes-recapitalization-of-navitas-life-sciences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"H.I.G. Capital Completes Recapitalization of Navitas Life Sciences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"H.I.G. Capital Completes Recapitalization of Navitas Life Sciences - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/h-i-g-capital-completes-recapitalization-of-navitas-life-sciences\/","og_locale":"en_US","og_type":"article","og_title":"H.I.G. Capital Completes Recapitalization of Navitas Life Sciences - Pharma Trend","og_description":"MIAMI–(BUSINESS WIRE)–#BlueChipClients–H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with over $50 billion of equity capital under management, is pleased to announce that one of its affiliates has completed the recapitalization of Navitas Life Sciences (\u201cNavitas\u201d or the \u201cCompany\u201d). Headquartered in Princeton, NJ, Navitas is a global technology-enabled clinical research organization (CRO) providing outsourced ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/h-i-g-capital-completes-recapitalization-of-navitas-life-sciences\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-13T10:01:59+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220913005455\/en\/1116880\/21\/New_HIGCapital.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/h-i-g-capital-completes-recapitalization-of-navitas-life-sciences\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/h-i-g-capital-completes-recapitalization-of-navitas-life-sciences\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"H.I.G. Capital Completes Recapitalization of Navitas Life Sciences","datePublished":"2022-09-13T10:01:59+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/h-i-g-capital-completes-recapitalization-of-navitas-life-sciences\/"},"wordCount":627,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/h-i-g-capital-completes-recapitalization-of-navitas-life-sciences\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220913005455\/en\/1116880\/21\/New_HIGCapital.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/h-i-g-capital-completes-recapitalization-of-navitas-life-sciences\/","url":"https:\/\/pharma-trend.com\/en\/h-i-g-capital-completes-recapitalization-of-navitas-life-sciences\/","name":"H.I.G. Capital Completes Recapitalization of Navitas Life Sciences - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/h-i-g-capital-completes-recapitalization-of-navitas-life-sciences\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/h-i-g-capital-completes-recapitalization-of-navitas-life-sciences\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220913005455\/en\/1116880\/21\/New_HIGCapital.jpg","datePublished":"2022-09-13T10:01:59+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/h-i-g-capital-completes-recapitalization-of-navitas-life-sciences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/h-i-g-capital-completes-recapitalization-of-navitas-life-sciences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/h-i-g-capital-completes-recapitalization-of-navitas-life-sciences\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220913005455\/en\/1116880\/21\/New_HIGCapital.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220913005455\/en\/1116880\/21\/New_HIGCapital.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/h-i-g-capital-completes-recapitalization-of-navitas-life-sciences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"H.I.G. Capital Completes Recapitalization of Navitas Life Sciences"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48291","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48291"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48291\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48291"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48291"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48291"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}